Skip to main
MEDP

Medpace Holdings (MEDP) Stock Forecast & Price Target

Medpace Holdings (MEDP) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 0%
Buy 9%
Hold 64%
Sell 9%
Strong Sell 18%

Bulls say

Medpace Holdings is poised for growth, with expectations of passthrough revenues increasing by 200-300 basis points in the second half of the year, compared to elevated levels in the second quarter. The company is experiencing positive momentum due to higher request-for-proposal (RFP) volumes observed in the first quarter, pointing to robust demand for its services. Additionally, Medpace anticipates a strong book-to-bill ratio, potentially exceeding 1.15x in the third quarter, reflecting healthy operational efficiency and demand stability.

Bears say

Medpace Holdings has experienced backlog cancellations that remain at the upper range of normal, indicating potential instability in customer demand. Despite a slight improvement in cancellations in Q2, the company has not provided quantifiable projections for growth in Direct Service revenue, contributing to uncertainty regarding future revenue streams. Additionally, the updated adjusted EBITDA estimates for 2025 and 2026 have been revised upward, but this adjustment reflects rising direct service costs and anticipated declines in passthroughs, highlighting ongoing concerns about cost management and profitability.

Medpace Holdings (MEDP) has been analyzed by 11 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 9% recommend Buy, 64% suggest Holding, 9% advise Selling, and 18% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medpace Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medpace Holdings (MEDP) Forecast

Analysts have given Medpace Holdings (MEDP) a Hold based on their latest research and market trends.

According to 11 analysts, Medpace Holdings (MEDP) has a Hold consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $468.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $468.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medpace Holdings (MEDP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.